Trial Profile
Randomized, double-blind, placebo-controlled, dose-increased clinical trials of dose groups to assess safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics after repeated oral administration of AVI-CO-004 for 10 days to male HIV-infected subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs AVI CO 004 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVI-P1-DB003
- Sponsors Avixgen
- 28 Jun 2018 According to Ebixen media release, studybis expected to start in the second half of the year.
- 20 Mar 2018 New trial record
- 03 Mar 2018 According to Ebixen media release, the Korea Food and Drug Administration (KFDA) approved AVI-CO-004 for phase 2 study.